Braeburn Pharmaceuticals pulled its plans for a $150 million initial public offering yesterday, citing unstable market conditions.
The Princeton, N.J.-based company 1st announced plans to go public in late December and in mid-January, Braeburn said it planned to raise $150 million by offering 7,692,308 shares of its common stock at $18.00 to $21.00 apiece.
The company has developed a 6-month buprenorphine implant for the treatment of opioid addiction – the 1st device of its kind to be approved by the FDA.
Get the full story at our sister site, Drug Delivery Business News.